Background
Methods
Tumer cell lines
Patients and human tissues
Clinicopathological factors | TLR4 | MyD88 | MyD88+ | ||||||
---|---|---|---|---|---|---|---|---|---|
High | Low | Positive | Negative | High | Low | ||||
(n = 67 ) | (n = 16 ) | P-value | (n = 64 ) | (n = 19 ) | P-value | (n = 28 ) | (n = 36 ) | P-value | |
Age(years) | |||||||||
≥55 | 32 | 11 | 0.1311 | 29 | 14 | 0.0268 | 11 | 18 | 0.2743 |
<55 | 35 | 5 | 35 | 5 | 17 | 18 | |||
Pathology | |||||||||
Serous | 50 | 12 | 0.6249 | 46 | 15 | 0.3850 | 21 | 25 | 0.4190 |
Other | 17 | 4 | 18 | 4 | 7 | 11 | |||
Histological grade | |||||||||
Well /Moderate | 23 | 6 | 0.5135 | 25 | 4 | 0.1192 | 15 | 10 | 0.0328 |
Poor/ Clear cell | 44 | 10 | 39 | 15 | 13 | 26 | |||
FIGO Stage | |||||||||
I, II | 11 | 1 | 0.2742 | 9 | 3 | 0.5528 | 5 | 4 | 0.3393 |
III, IV | 56 | 15 | 55 | 16 | 23 | 32 | |||
Malignant cells in ascites | |||||||||
Yes | 34 | 4 | 0.0555 | 32 | 6 | 0.1240 | 12 | 20 | 0.2250 |
No | 33 | 12 | 32 | 13 | 16 | 16 | |||
Lymph node metastasis | |||||||||
Yes | 20 | 2 | 0.1345 | 20 | 2 | 0.0610 | 15 | 5 | 0.0008 |
No | 47 | 14 | 44 | 17 | 13 | 31 | |||
Liver or lung metastasis | |||||||||
Yes | 25 | 4 | 0.2666 | 27 | 2 | 0.0087 | 16 | 11 | 0.0298 |
No | 42 | 12 | 37 | 17 | 12 | 25 | |||
Residual tumor | |||||||||
>1 | 32 | 6 | 0.3244 | 32 | 6 | 0.1240 | 14 | 18 | 0.5993 |
<1 | 35 | 10 | 32 | 13 | 14 | 18 |
SDS-PAGE and Western blots
Immunohistochemistry for TLR4 and MyD88
Evaluation of immunohistochemical findings
Statistical analysis
Results
Expression of TLR4 and MyD88 in ovarian cancer cell lines and tissues
Clinicopathological significance of TLR4 and MyD88
Negative | Low | Negative | High | Negative + low | High | ||||
---|---|---|---|---|---|---|---|---|---|
Clinicopathological factors | (n = 19 ) | (n = 36 ) | P-value | (n = 19 ) | (n = 28 ) | P-value | (n = 55 ) | (n = 28 ) | P-value |
Age(years) | |||||||||
≥55 | 14 | 18 | 0.0787 | 14 | 11 | 0.0208 | 32 | 11 | 0.0811 |
<55 | 5 | 18 | 5 | 17 | 23 | 17 | |||
Histological grade | |||||||||
Well /Moderate | 4 | 10 | 0.4202 | 4 | 15 | 0.0256 | 14 | 15 | 0.0113 |
Poor/ Clear cell | 15 | 26 | 15 | 13 | 41 | 13 | |||
Lymph node metastasis | |||||||||
Yes | 2 | 5 | 0.5412 | 2 | 15 | 0.0026 | 7 | 15 | 0.0001 |
No | 17 | 31 | 17 | 13 | 48 | 13 | |||
Liver or lung metastasis | |||||||||
Yes | 2 | 11 | 0.0888 | 2 | 16 | 0.0012 | 13 | 16 | 0.0029 |
No | 17 | 25 | 17 | 12 | 42 | 12 |
Clinicopathological parameters and patient survival in EOC
Variable | 5-Year DFS HR (95 % CI) | P-value | 5-Year OS HR (95 % CI) | P-value |
---|---|---|---|---|
A. univariate analysis
| ||||
Age (≥55 years vs <55 years) | 0.77(0.43-1.36) | 0.3659 | 0.76(0.38-1.51) | 0.4313 |
Pathology (serous vs other) | 0.51(0.24-1.09) | 0.0833 | 0.69(0.29-1.67) | 0.4100 |
Histological grade (poor vs well/moderate) | 0.61(0.34-1.07) | 0.0859 | 0.73(0.37-1.43) | 0.3587 |
FIGO stage (III/IV vs I/II) | 5.95(1.44-24.55) | 0.0137 | 8.41(1.14-62.03) | 0.0368 |
Malignant cells in ascites (yes vs no) | 1.96(1.09-3.51) | 0.0242 | 1.59(0.79-3.20) | 0.1913 |
Lymph node metastasis (yes vs no) | 3.29(1.99-6.03) | 0.0001 | 2.55(1.28-5.07) | 0.0076 |
Liver or lung metastasis (yes vs no) | 4.28(2.35-7.80) | <0.001 | 3.62(1.81-7.25) | 0.0003 |
Residual tumor (>1 vs <1) | 2.04(1.14-3.66) | 0.0164 | 1.81(0.90-3.63) | 0.0950 |
TLR4 (high vs low) | 1.78(0.79-4.02) | 0.1657 | 1.68(0.67-4.19) | 0.2685 |
MyD88 (positive vs negative) | 0.10(0.02-0.41) | 0.0014 | 0.09(0.01-0.67) | 0.0185 |
B. multivariate analysis
| ||||
FIGO stage (III/IV vs I/II) | 4.57(1.04-20.17) | 0.0446 | 7.89(1.03-58.90) | 0.0468 |
Malignant cells in ascites (yes vs no) | 1.38(0.73-2.60) | 0.3255 | —— | —— |
Lymph node metastasis (yes vs no) | 1.25(0.62-2.52) | 0.5315 | 0.94(0.43-2.05) | 0.8713 |
Liver or lung metastasis (yes vs no) | 2.21(1.05-4.69) | 0.0380 | 2.47(1.13-5.41) | 0.0237 |
Residual tumor (>1 vs <1) | 1.04(0.54-1.99) | 0.9082 | —— | —— |
MyD88 (high vs low) | 0.11(0.23-0.47) | 0.0027 | 0.12(0.02-0.89) | 0.0382 |